Recent News

• 05.20.2025 - 3rd Annual H.C. Wainwright BioConnect Investor Conference
• 05.14.2025 - Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
• 05.09.2025 - Protalix Biotherapeutics First Quarter 2025 Financial and Business Results Conference Call
• 05.09.2025 - Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
• 05.05.2025 - Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
• 03.25.2025 - iAccess Alpha Virtual Best Ideas Spring Conference 2025
• 03.24.2025 - Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
• 03.18.2025 - Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting
• 03.17.2025 - Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call
• 03.17.2025 - Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Recent Filings

• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - EX-99.1 EX-99.1
• 05.09.2025 - 8-K Current report
• 05.08.2025 - ARS Annual Report to Security Holders
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.28.2025 - S-3 Registration statement under Securities Act of 1933
• 04.23.2025 - 8-K Current report
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - 8-K Current report
• 03.17.2025 - 8-K Current report